Montreal, December 5, 2016 – The NEOMED Institute announced today that Max Fehlmann will be stepping down from his position of CEO of the NEOMED Institute and NEOMED‐LABS at the end of the year. Max, together with Philippe Walker, Chief Scientific Officer of the NEOMED Institute, founded the NEOMED Institute in 2012. Under Max’s leadership, NEOMED has matured into a major Life Sciences hub in Canada with 2 state‐of‐the art drug discovery sites in Ville St Laurent and Laval, Quebec. The Institute, which has a primary mission to bridge academic innovations with the pharmaceutical industry, has developed an impressive pipeline of innovative projects including preclinical and clinical programs with a dedicated team of scientists and clinicians. Max was also instrumental in the creation of NEOMED‐LABS, an affiliated Contract Research Organization (CRO) employing over 60 scientists, technicians and support staff, specialized in and dedicated to the development and processing of immunoassays for clinical vaccine development.
Commenting on Max’s decision to step down, the Board of Directors of the NEOMED INSTITUTE noted: “Max’s vision and drive has led to the establishment of a world class biotechnology hub in Montreal, Quebec. The NEOMED Institute has, through its legacy programs and partnering efforts with Canadian and international universities and companies, developed an innovative and proprietary pipeline of therapeutics, which it will out‐license at appropriate time points. It has also provided quality laboratory and office space to over 30 companies employing over 300 highly skilled people across our two sites. Max has laid a strong foundation for the NEOMED Institute, including significant ongoing support from our pharmaceutical partners, the Government of Quebec and the Government of Canada, and we are extremely confident that we will be able to continue to build on this foundation to ensure that NEOMED continues to grow into its role as a sustainable and important actor in the national healthcare infrastructure. We are also very pleased that Max will be continuing to provide his advice and counsel to NEOMED through his continued role as a board member of the NEOMED Institute and our affiliate CRO, NEOMED‐LABS.”
Donald Olds, the Chairman of the Board of the NEOMED Institute, has been named Executive Chairman & Interim CEO to maintain the momentum of the organization in the early months of the transition and Luc Vachon, currently Chairman of the Board of NEOMED‐LABS, has been appointed Interim CEO of NEOMED‐LABS. In addition, Phillipe Walker, Chief Scientific Officer of NEOMED Institute has been named General Manager for NEOMED’s R&D programs and Pierre‐Yves Desbiens, VP Finance and Operations of NEOMED Institute has been named General Manager for the NEOMED Campus (building and services).
ABOUT THE NEOMED INSTITUTE
The NEOMED Institute is a not‐for‐profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favorable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint‐Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
ABOUT NEOMED LABS
NEOMED‐LABS is a Contract Research Organization (CRO) offering high‐quality clinical immunology laboratory services. NEOMED‐LABS serves pharmaceutical corporations, biotechnology companies, and healthcare / non‐profit organizations with its extensive expertise in delivering quality readouts for the clinical development of vaccines and immunotherapies. Currently, NEOMED‐LABS supports clinical vaccine development programs of multinational pharma companies. The staff consists of over 60 experienced, dedicated scientists and technical experts, and the projects are supported by an extensive network of key opinion leaders as scientific advisors and consultants. NEOMED‐LABS conducts GCLP‐ compliant immune‐monitoring activities to support Phase I to Phase IV vaccine clinical trials. Located in Laval (Quebec, Canada), an important scientific hub in North America the company benefits from cutting‐edge technology platforms and state‐of‐the‐art laboratories with BSL 2 and BSL 3 facilities.
For more information, please visit our website: www.neomedlabs.com
For more information, please contact: